CGMs are wearables that help measure blood sugar and can be used with insulin pumps. Dexcom, a CGM manufacturer based in San Diego, said it analyzed Optum insurance claims and found CGM use doubled among patients with insulin regimens after they began taking a GLP-1 drug. For patients that use basal insulin or non-insulin therapies, CGM use nearly quadrupled after taking GLP-1s.
Dexcom said its findings are in contrast to industry concerns that GLP-1 drugs may lead to less usage of diabetes monitoring products.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
